Professor Paolo Pozzilli MD trained in Medicine and specialized in Endocrinology & Metabolic Diseases from Sapienza University of Rome, Italy, under the guidance of Professor Domenico Andreani. Since then he worked mainly in the field of diabetes with particular focus to type 1 diabetes (T1D) pathogenesis and prevention in Rome and UK and in collaboration with several investigators worldwide. He has published over 500 papers, books and reviews on different aspects of diabetes, from basic studies on the autoimmune mechanisms of T1D to clinical trials testing novel therapies for T2D.
Internationally he set up with others the EURODIAB study on the incidence of childhood T1D, that is the most comprehensive mapping of the incidence of T1D in Europe. He has been the regional P.I. for TRIGR, the longest trial for the primary prevention of T1D. He established a joint international PhD programme in diabetes including 4 Universities (Barts & the London, Queen Mary, UK; University of Ulm, Germany; University of Barcelona, Spain and University Campus Bio-Medico of Rome, Italy: The most relevant international studies in which he acted as Leader or regional P.I. include ENDIT, TRIGR, ROADMAP, ELIXA, DEFEND, GAD, Action LADA and more recently EMPAREG, EXSCEL, CANVAS and inTANDEM3 trials. His collaborations with investigators in Europe, US and more recently China, have allowed him to implement joint research programs for the identification of T1D pathogenic mechanisms leading to beta cell destruction. He continues to serve as consultant on diabetes in countries including China, UAE, Egypt, Kuwait and, in Europe, Belgium, Finland, Spain, Poland, Sweden. In the early 2000s and for 10 years he has been a member of the scientific review committee of the Juvenile Diabetes Research Foundation (USA). He has also served for the EU in the grant selection for the 5th Framework Programme. He is currently the Editor in Chief of Diabetes Metabolism Research & Reviews.
In Italy, he is the Director of the Department of Endocrinology & Diabetes, at Campus Bio-Medico University of Rome and of the Post-Graduate School of Endocrinology and Metabolism at the same University where he is also Coordinator of the PhD program in Integrated Biomedical Sciences and Bioethics. He is also Chairman of Master’s Degree Program in Medicine and Surgery in English. He was President of the Italian Society of Diabetes for Lazio and Rome region, founder and Chairman in the late 80’s of the IMDIAB group (immunotherapy of T1D) with participation of several diabetes hospital centers in Rome, leading to the conduction of 13 clinical trials in the specific field. Currently is the Coordinator of the Italian Society of Endocrinology for Lazio and Rome region.
In the UK, he has worked at the Centre of Diabetes, St. Bartholomew’s and the London School of Medicine, Queen Mary, University of London, initially under the guidance of the late Professor Andrew Cudworth at St. Bartholomew’s Hospital. He continued his activity at the Centre of Diabetes, Blizard Institute, Queen Mary on a project on Latent Autoimmune Diabetes in Adults (LADA) being Deputy Leader of the EU funded programme ACTION LADA.
Professor Pozzilli has received several awards, the most significant ones include the Andrew Cudworth Memorial Award by the British Diabetic Association (1984), the Morgagni Award for Best Young Investigator by the International Society of Metabolism (1989), the Award <45 years of age by the Italian Society of Diabetes (1994), the Marie Kugel Award by the Juvenile Diabetes Foundation (USA (2007), the Diabetes Honoris Causa by the Paulescu Foundation, Romanian Diabetes Society (2013), the Celso Prize by the Italian Society of Diabetes (2014) and the Menarini Award, Joseph Hoet Memorial Lecture by the World Foundation on Diabetes Prevention (2016). He has published 515 papers (Pubmed) in diabetes and related fields.